To study incidence, risk factors for Second Primary Malignancy in Myelofibrosis and outcome in Ruxolitinib-treated Myelofibrosis Patients patients
Latest Information Update: 12 Oct 2021
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 20 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association